Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Many Greek medical doctors prescribe expensive proton pump inhibitors for everything, in order to “protect the stomach” from various other pills or therapies.
This widespread off label use of proton pump inhibitors in my Country is the result of under the table deals with pharmaceutical Companies. [3]
Despite increasing debt, Greece continues to spend the most on pharmaceuticals. [1]
Results from this research study demonstrate that this practice is harmful both financially and clinically. [2]
Let us hope Ministry officials in Greece manage to limit this phenomenon.
Competing interests:
Dr Stavros Saripanidis is a diligent Greek taxpayer who pays for all these expensive pharmaceuticals that get prescribed for presumed off label benefits.
Re: GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugs
Dear Editors,
Many Greek medical doctors prescribe expensive proton pump inhibitors for everything, in order to “protect the stomach” from various other pills or therapies.
This widespread off label use of proton pump inhibitors in my Country is the result of under the table deals with pharmaceutical Companies. [3]
Despite increasing debt, Greece continues to spend the most on pharmaceuticals. [1]
Results from this research study demonstrate that this practice is harmful both financially and clinically. [2]
Let us hope Ministry officials in Greece manage to limit this phenomenon.
References
[1] http://www.bmj.com/content/343/bmj.d4803?tab=responses
[2] http://www.bmj.com/content/344/bmj.e372
[3] http://www.bmj.com/content/342/bmj.d2408?tab=responses
Competing interests: Dr Stavros Saripanidis is a diligent Greek taxpayer who pays for all these expensive pharmaceuticals that get prescribed for presumed off label benefits.